Antipsychotic medication utilization trends among Texas veterans: 1997-2002

Annals of Pharmacotherapy

Volumn 42, Issue 9, 2008, Pages 1229-1238

  Yang, Min ^a,e   Barner, Jamie C ^b   Lawson, Kenneth A ^b   Rascati, Karen L ^b   Wilson, James P ^b   Crismon, M Lynn ^b   Worchel, Jason ^c   Mascarenas, Cynthia A ^d  

^a QualityMetric   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^e QualityMetric Health Outcomes Solutions   (United States)

Author keywords

Antipsychotic; Medication utilization; Trends

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; COMBINATION CHEMOTHERAPY; COMORBIDITY; DEPRESSION; DRUG CHOICE; DRUG SUBSTITUTION; DRUG UTILIZATION; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREND STUDY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MENTAL DISORDERS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; TEXAS; VETERANS;

EID: 50249088668     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L155     Document Type: Article

References (55)

1. Kraepelin E. Psychiatrie. Leipzip: Barth;1899.
2. Kraepelin E. Dementia praecox 1896 (Translated from Lehrbuch der Psychiatrie. Leipzig: Barth). In: Cutting J, Shepherd M, eds. The clinical roots of the schizophrenia concept. Cambridge, UK: Cambridge University Press, 1987.
3. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001;52:503-17.
4. Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 2000;57:238-58.
5. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
6. Davis JM, Chen N. Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull 2002;28:43-61.
7. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
8. DeQuado JR, Tandon R. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia? J Psychiatr Res 1998;32:229-42.
9. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-12.
10. Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996;6(S2):13-20.
11. Keefe RS, Bilder RM, Davis SM, et al. CATIE Investigators. Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psych 2007;64:633-47.
12. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 1996;57(suppl 11):68-71.
13. Miller AL, Hall CS, Buchanan RW, et al. The Texas Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004;65:500-8
14. Crismon ML, Dorson PG. Schizophrenia. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy - a pathophysiology approach. 5th ed. New York: McGraw Hill, 2002.
15. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
16. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68:1751-62.
17. Kapur S, Remington G. Atypical antipsychotics: patients value the lower incidence of extrapyramidal side effects. BMJ 2000;321:1360-1.
18. Peuskens J. The evolving definition of treatment resistance. J Clin Psychiatry 1999;60(suppl 12):4-8.
19. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004;161:700-6.
20. Potter WZ, Ko GN, Zhang LD, Yan PN. Clozapine in China. A review and preview of US/PRC collaboration. Psychopharmacology 1989;99:S87-S97.
21. DeGroot IW, Heck AH, VanHarten PN. Addition of risperidone to clozapine therapy in chronically psychotic inpatient (letter). J Clin Psychiatry 2001;62:129-30.
22. Botts S, Hines HH, Littrell R. Antipsychotic polypharmacy in the ambulatory care setting, 1993-2000. Psychiatr Serv 2003;54:1086.
23. Clark RE, Bartels SJ, Mellman TA, Peacock WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002;28:75-84.
24. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004;11:313-27.
25. Brunnello N, Masotto C, Steardo L, Markstein R, Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 1995;13:177-213.
26. Stahl SM. Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? J Clin Psychiatry 1999;60:425-6.
27. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 1999;60(suppl 10):20-30.
28. Pincus HA, Zarin DA, Tanielian TL, et al. Psychiatric patients and treatment in 1997: findings from the American Psychiatric Practice Research Network. Arch Gen Psychiatry 1999;56:441-9.
29. Taylor D, Mace S, Mir S, Kerwin R. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatry in Clin Prac 2000;4:41-6.
30. Williams C, Johnstone B, Kesterson J, Javor K, Schmetzer A. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 1999;37:AS81-6.
31. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003;12:41-8.
32. Levin J, Jaffe AB. Antipsychotic medication utilization in a state mental hospital system, 1994-2000. In: Manderscheid RW, Henderson MJ, eds. Mental Health, United States, 2002. DHHS Pub No. (SMA) 3938 Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.
33. National Cholesterol Education Program; National Heart, Lung, and Blood Institute; National Institutes of Health. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Final Report. www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf (accessed 2008 May 19).
34. National High Blood Pressure Education Program; National Institutes of Health; National Heart, Lung, and Blood Institute. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. www.nhlbi.nih.gov/guidelines/hypertension/express.pdf (accessed 2008 May 19).
35. Martin BC, Miller LS, Kotzan JA. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts. Schizophr Res 1999;47:281-92.
36. Grohmann R, Engel R, Geissler K, Rüther E. Psychotropic drug use in psychiatric inpatients: recent trends and changes over time - data from the AMSP study. Pharmacopsychiatry 2004;37(suppl 1):S27-38.
37. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-6.
38. Sowell M, Mukhopadhyay N, Cavazzoni P, et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 2003;88:5875-80.
39. Fuller MA, Shermock KM, Secic M, Grogg AL. Comparative study of development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003;23:1037-43.
40. Lee DW, Fowler RB, Kadlubek PJ, Haberman M. No significant difference in diabetes risk during treatment with typical versus atypical antipsychotics: results from a large observational study. Drug Benefit Trends 2002;14:46-52.
41. Department of Veterans Affairs. Recommendations for atypical antipsychotic use in schizophrenia and schizoaffective disorders. www.pbm.va.gov/default.aspx (accessed 2008 Jan 23).
42. Association AP. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(suppl 4):1-50.
43. Acquaviva E, Gasquet I, Falissard B. Psychotropic combination in schizophrenia. Eur J Clin Pharmacol 2005;61:855-61.
44. Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 2004;65:975-81.
45. Kozaric-Lovacic D, Pivac N, Muck-Seler D, Rothbaum BO. Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. J Clin Psychiatry 2005;66:922-7.
46. Ahearn EP, Krohn A, Connor KM, Davidson JRT. Pharmacologic treatment of posttraumatic stress disorder: a focus on antipsychotic use. Ann Clin Psychiatry 2003;15:193-201.
47. Green AI. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J Clin Psychiatry 2005;66(suppl 6):21-6.
48. Noordsy DL, Green AI. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Curr Psychiatry Rep 2003;5:340-6.
49. Suh GH, Shall A. Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home. Int Psychogeriatr 2005;17:429-41.
50. Weiss E, Hummer M, Koller D, Ulmer H, Fleischharker WW. Off-label use of antipsychotic drugs. J Clin Psychopharmacol 2000;20:695-8.
51. Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 1999;37(4 suppl Lilly):AS81-6.
52. Leslie DL, Rosenheck RA. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am J Psychiatry 2002;159:1534-40.
53. Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005;5:26. DOI 10.1186/1471-244X-5-26
54. Daumit GL, Crum RM, Guallar E, et al. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Arch Gen Psychiatry 2003;60:121-8.
55. Kilbourne AM, Pincus HA. Patterns of psychotropic medication use by race among veterans with bipolar disorder. Psychiatr Serv 2006;57:123-6.